AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01774071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr- DFO-MSTP2109A
Description: If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan.
Study NCT01774071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr DFO-MSTP2109A
Description: If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2
Study NCT03880955 — intervention group
Intervention type: DEVICE
Intervention: ReUnion RSA System
Description: The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
Study NCT04603911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.
Study NCT04603911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, epinephrine, dexamethasone, and clonidine
Description: The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
Study NCT04062162 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking football training
Description: Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
Study NCT02720263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: Oral
Study NCT02720263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 once every 2 weeks for 4 cycles.
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
Study NCT00743223 — intervention group
Intervention type: OTHER
Intervention: The measure of the cervical posture
Description: The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT02957968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03207698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone
Study NCT03207698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
Study NCT04336319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: 1. At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~2. FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline).
Study NCT03207698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
Study NCT00574626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSCT
Description: Peripheral Blood Stem Cell Transplant
Study NCT00574626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Transplant
Description: Bone Marrow Transplant
Study NCT03433209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure device
Description: Vessel-sealing device used for laparoscopic hysterectomy
Study NCT03433209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articulating Enseal
Description: Vessel-sealing device used for laparoscopic hysterectomy
Study NCT00287872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00287872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study NCT03305458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TFCBT
Description: treatment as usual
Study NCT03305458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTFCBT
Description: tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
Study NCT02913404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: standard surgical procedure
Study NCT02913404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Recon. extra-articular-tenodesis
Description: standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
Study NCT04519320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary function testing
Description: D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan~* Pulmonary function testing (PFT)~* 6-minute walk test (6MWT)~* MOS SF-36 Questionnaire~* HADS scale~* Ventilatory polygraphy~M6: D0 + 6 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~M12: D0 + 12 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan (If anomaly found at M3)~* PFT~* Pulmonary Exercise Stress Test~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO \<LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale
Study NCT03467061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice
Description: concentrated beetroot juice
Study NCT03467061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: concentrated beetroot juice
Study NCT03467061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mouthwash
Description: 2 x 10 mL antibacterial mouthwash per day for 14 days
Study NCT00555919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonaprisan (ZK 230211, BAY86-5044)
Description: 25 mg daily oral treatment
Study NCT00555919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonaprisan (ZK 230211, BAY86-5044)
Description: 100 mg daily oral treatment
Study NCT00832845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST plus treatment as usual
Description: Patients will receive CBSST in addition to their regular treatment for 36 weeks.
Study NCT00832845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
Study NCT00020943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg subQ daily day 4 until ANC >10,000 (or ANC> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
Study NCT00020943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 15 mg/kg IV infusion over 2 hours Day 6, Tx 4
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/sq m IVP Day 3, Tx 1\& 2
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg/sq m PO Days 3-7, Tx 1 \& 2
Study NCT00020943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/sq m IVP Day 3, Tx 1 \& 2
Study NCT00020943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
Study NCT00856869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
Study NCT01297439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: suctioning of fetal nose and mouth during delivery
Description: Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes).
Study NCT01297439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pushing maneuver
Description: The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia.
Study NCT03384836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03384836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03384836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO
Study NCT03718481 — intervention group
Intervention type: OTHER
Intervention: ARCP Process
Description: One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training \[1\]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
Study NCT04081025 — intervention group
Intervention type: OTHER
Intervention: EpiWux
Description: A cross-sectional and longitudinal study including a questionnaire and a clinical examination
Study NCT00611949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geranium oil
Description: 2 applications of topical oil per week for 2 weeks
Study NCT01598298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Given PO
Study NCT01598298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT02601937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Study NCT04701229 — intervention group
Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
Study NCT02272309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and EP measurement
Study NCT03783403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days
Study NCT02954796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD352A
Description: On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
Study NCT06741124 — intervention group
Intervention type: PROCEDURE
Intervention: Channel Esophagogastrostomy
Description: Channel Esophagogastrostomy
Study NCT06741124 — intervention group
Intervention type: PROCEDURE
Intervention: Double Tract Reconstruction
Description: Double Tract Reconstruction
Study NCT06755164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous aerobic and cognitive training (SIM)
Description: The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.
Study NCT06755164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential aerobic and cognitive training (SEQ)
Description: The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
Study NCT06766708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management lymphedema (SML) education program
Description: The content of the booklet was prepared based on literature review.. In addition to the above intervention methods, the phone number of each patient was taken and the patients were followed up by phone for 12 months. For this purpose, the patient was asked to fill in the compliance chart prepared in order to monitor the patient's compliance and was checked by the researcher every two weeks by phone call. By phone call; compliance with skin care, SLD, compression garments and exercise practices included in the SMLEP were evaluated and recorded. Within the scope of the SMLEP, the patients were asked to do exercises and SLD at least 3 days a week and 2 times a day (morning and evening) for 12 months. It was recommended to wear compression garments, especially during exercises and throughout the day.
Study NCT03783403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days
Study NCT03783403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study NCT01343277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Study NCT01343277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Study NCT00342381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-diaminopyridine
Description: Single dose 3,4 diaminopyridine
Study NCT00342381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo treatment
Study NCT03193112 — intervention group
Intervention type: DRUG
Intervention: Agomelatine 25 MG Oral Tablet
Description: We will treat our patients with Agomelatine tablet of 25 mg.
Study NCT01068886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External pancreatic stent
Description: stent through pancreatic anastomosis
Study NCT01881204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin and Calcilock
Description: Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
Study NCT01881204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: Hesperidin (552mg) will be administered in the form of cookies (biscuit).
Study NCT01881204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Cookies without Hesperidin or Calcilock added.
Study NCT03132064 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: surgical repair for end stage of knee osteoarthritis.
Study NCT05140629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baobab fruit aqueous extract
Description: After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
Study NCT01201603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange juice
Description: 250ml of orange juice or a sugars matched orange drink
Study NCT01201603 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: orange juice
Description: 250ml of orange juice or a sugars matched orange drink
Study NCT00433615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
Study NCT00433615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
Study NCT04112225 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.